Skip to main content
. 2020 Feb 6;12(2):137. doi: 10.3390/pharmaceutics12020137

Figure 3.

Figure 3

Dissolution profiles of nilotinib in simulated gastric fluid (SGF) from formulations F1–F3 (A) and C1–C6 (B).